ELOX vs. ALBT, GMDAQ, WINT, KRBP, FNCH, TCON, ACORQ, TCBP, ACOR, and SCNI
Should you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include Avalon GloboCare (ALBT), Gamida Cell (GMDAQ), Windtree Therapeutics (WINT), Kiromic BioPharma (KRBP), Finch Therapeutics Group (FNCH), TRACON Pharmaceuticals (TCON), Acorda Therapeutics (ACORQ), TC Biopharm (TCBP), Acorda Therapeutics (ACOR), and Scinai Immunotherapeutics (SCNI). These companies are all part of the "biological products, except diagnostic" industry.
Avalon GloboCare (NASDAQ:ALBT) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.
Avalon GloboCare has higher revenue and earnings than Eloxx Pharmaceuticals. Avalon GloboCare is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avalon GloboCare had 1 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 1 mentions for Avalon GloboCare and 0 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 1.89 beat Avalon GloboCare's score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the media.
Avalon GloboCare has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of 2.71, meaning that its share price is 171% more volatile than the S&P 500.
Eloxx Pharmaceuticals has a net margin of 0.00% compared to Eloxx Pharmaceuticals' net margin of -1,304.14%.
Eloxx Pharmaceuticals received 13 more outperform votes than Avalon GloboCare when rated by MarketBeat users.
1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 64.0% of Avalon GloboCare shares are held by company insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Eloxx Pharmaceuticals has a consensus price target of $55.00, suggesting a potential upside of 6,662.32%. Given Avalon GloboCare's higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Avalon GloboCare.
Summary
Avalon GloboCare beats Eloxx Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Eloxx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eloxx Pharmaceuticals Competitors List
Related Companies and Tools
